![]() 31, 2022 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.BOSTON, Mass., Aug. The company was formerly known as Panacea Pharmaceuticals, Inc. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. Press Release: Sensei Biotherapeutics Reports -2-Īctivity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei's product candidates t Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of Press Release: Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Sensei Biotherapeutics 2Q Loss/Shr 34c >SNSE Sensei expects its current cash balance to fund operati Sensei Biotherapeutics expects cash to fund operations into 1Q25Ĭash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $1 Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06 The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06 Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) released its earnings results on Tuesday. Sensei Biotherapeutics (NASDAQ:SNSE) Announces Earnings Results, Beats Expectations By $0.06 EPS (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participa ![]() 23, 2022 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. ![]() Sensei Biotherapeutics to Participate in Upcoming Investor ConferencesīOSTON, Aug. ![]() (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today reported preliminary preclinical data fro Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a PH-selective VISTA-blocking AntibodyīOSTON, Mass., Aug. Sensei Biotherapeutics Says Antibody SNS-101 Shows Favorable Pharmacokinetic, Immunologic Effects in Preclinical DataĠ9:03 AM EDT, (MT Newswires) - Sensei Biotherapeutics (SNSE) said Wednesday that preclinical data from studies of antibody SNS-101, which targets the immune checkpoint V-domain Ig suppress (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer 21, 2022 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science Into SurvivalīOSTON, Sept. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |